Abstract
Non-Hodgkin's lymphoma of the bone is a very rare disease that accounts for approximately 5% of all extranodal non-Hodgkin's lymphomas and for 7–10% of primary bone tumours. We report the case of a 28-year-old man who, in June 2001, presented with a right humerus showing painful destructive lesions with pathological fractures. Biopsy revealed diffuse, large B-cell non-Hodgkin's lymphoma expressing CD20. The patient received six cycles of conventional chemotherapeutic regimen, including cyclophosphamide, doxorubicin, vincristine and prednisone, and VP-16 (etoposide), ifosfamide and mitoxantrone. His arm pain worsened, and x-rays demonstrated progressive disease. He began a trial of rituximab, 750 mg/week, for 4 weeks. There was improvement in pain after the first infusion. Radiographic studies conducted 3 months after rituximab therapy showed marked improvement in his humerus disease. MRI showed a decrease of tumour volume with residual minor signal abnormalities of the bone marrow. He had no evidence of recurrent lymphoma 24 months later.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ostrowski ML, Unni KK, Banks PM, Shives TC, Evans RG, O'Connell MJ et al (1986) Malignant lymphoma of bone. Cancer 58:2646–2655
Parker F, Jackson H (1939) Primary reticulum cell sarcoma of bone. Surg Gynecol Obstet 68:45–53
Fidias P, Spiro I, Sobczak ML, Nielsen GP, Ruffolo EF, Mankin H et al (1999) Long-term results of combined modality therapy in primary bone lymphomas. Int J Radiat Oncol Biol Phys 45:1213–1218
Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D et al (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 92:1927–1932
Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90:2188–2195
Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF et al (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268–276
Savage DG, Staron R (2001) Rituximab for bone lymphoma. Ann Intern Med 134:1156–1157
Mengiardi B, Honegger H, Hodler J, Exner UG, Csherhati MD, Brühlmann W (2005) Primary lymphoma of bone: MRI and CT characteristics during and after successful treatment. AJR Am J Roentgenol 184:185–192
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Achemlal, L., Mikdame, M., Nouijai, A. et al. Dramatical improvement of chemoresistant bone lymphoma with rituximab. Clin Rheumatol 25, 394–395 (2006). https://doi.org/10.1007/s10067-005-0060-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-005-0060-x